Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cellular Oncology
Erschienen in: Cellular Oncology 2/2017

15.12.2016 | Review

Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer

verfasst von: Khalid El Bairi, Abdul Hafeez Kandhro, Adel Gouri, Wafaa Mahfoud, Noureddine Louanjli, Brahim Saadani, Said Afqir, Mariam Amrani

Erschienen in: Cellular Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

In spite of various treatment options currently available, ovarian cancer (OC) still remains a leading cause of death in women world-wide. Diagnosis at an early stage is one of the most important factors that determines survival. Current clinical diagnostic tools have, however, a limited efficacy in early OC detection. Therefore, there is a critical need for new (early) diagnostic biomarkers and tools. Through advances in genomic, proteomic and metabolomic techniques, several novel molecular OC biomarkers have recently been identified. These biomarkers are currently subject to validation. In addition, integration of genomic, proteomic and metabolomic data, in conjunction with epidemiologic and clinical data, is considered essential for obtaining useful results. Interesting recent work has already shown that specific diagnostic biomarkers, such as BRCA mutations, may have profound therapeutic implications. Here, we review the current state of OC research through literature and database searches, with a focus on various recently identified biomarkers via different technologies for the (early) diagnosis, prognosis and treatment of OC.

Conclusions

Multi-biomarker panels accompanied by a meticulous determination of their sensitivity and specificity, as well their validation, using multivariate analyses will be critical for its clinical application, including early OC detection and tailor-made OC treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, F. Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, 359–386 (2015)CrossRef
2.
R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2016. CA Cancer J. Clin. 66, 7–30 (2016)PubMedCrossRef
3.
R. Sankaranarayanan, R. Swaminathan, K. Jayant, H. Brenner, An overview of cancer survival in Africa, Asia, the Caribbean and Central America: the case for investment in cancer health services. IARC Sci. Publ. 162, 257–291 (2011)
4.
I. Cass, B.Y. Karlan, Ovarian cancer symptoms speak out – but what are they really saying? J. Natl. Cancer Inst. 102, 211–212 (2010)PubMedCrossRef
5.
K.A. Lowe, V.M. Chia, A. Taylor, C. O’Malleye, M. Kelsh, M. Mohamed, F.S. Mowat, B. Goff, An international assessment of ovarian cancer incidence and mortality. Gynecol. Oncol. 130, 107–114 (2013)PubMedCrossRef
6.
R. De Angelis, M. Sant, P.M. Coleman, S. Francisci, P. Baili, D. Pierannunzio, A. Trama, O. Visser, H. Brenner, E. Ardanaz, M. Bielska-Lasota, G. Engholm, A. Nennecke, S. Siesling, F. Berrino, R. Capocaccia, EUROCARE-5 working group, cancer survival in Europe 1999-2007 by country and age: results of Eurocare-5 – a population-based study. Lancet Oncol. 15, 23–34 (2014)PubMedCrossRef
7.
F. Dayyani, S. Uhlig, B. Colson, K. Simon, V. Rolny, D. Morgenstern, M. Schlumbrecht, Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer: a meta-analysis. Int. J. Gynecol. Cancer 26, 1586–1593 (2016)PubMedCrossRef
8.
J.L. Walker, C.B. Powell, L.M. Chen, J. Carter, V.L. Bae, L.P. Parker, M.E. Borowsky, R.K. Gibb, Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 121, 2108–2120 (2015)PubMedCrossRef
9.
10.
S. Lambrechts, D. Smeets, M. Moisse, E.I. Braicu, A. Vanderstichele, H. Zhao, E. Van, E. Berns, J. Sehouli, R. Zeillinger, S. Darb-Esfahani, D. Cacsire, D. Lambrechts, I. Vergote, Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. Eur. J. Cancer 53, 51–64 (2016)PubMedCrossRef
11.
M. Petrillo, C. Nero, G. Amadio, D. Gallo, A. Fagotti, G. Scambia, Targeting the hallmarks of ovarian cancer: the big picture. Gynecol. Oncol. 142, 176–183 (2016)PubMedCrossRef
12.
C. Santos, R. Sanz-Pamplona, E. Nadal, J. Grasselli, S. Pernas, R. Dienstmann, V. Moreno, J. Tabernero, R. Salazar, Intrinsic cancer subtypes-next steps into personalized medicine. Cell. Oncol. 38, 3–16 (2015)CrossRef
13.
A. Zaal, W.J. Peyrot, P.M. Berns, M.E. van der Burg, J.H. Veerbeek, J.B. Trimbos, I. Cadron, P.J. van Diest, W.N. van Wieringen, O. Krijgsman, G.A. Meijer, J.M. Piek, P.J. Timmers, I. Vergote, R.H. Verheijen, B. Ylstra, R.P. Zweemer, EORTC GCG translational research group, genomic aberrations relate early and advanced stage ovarian cancer. Cell. Oncol. 35, 181–188 (2012)CrossRef
14.
15.
J.J. Wallbillich, B. Forde, L.J. Havrilesky, D.E. Cohn, A personalized paradigm in the treatment of platinum-resistant ovarian cancer–a cost utility analysis of genomic-based versus cytotoxic therapy. Gynecol. Oncol. 142, 144–149 (2016)PubMedCrossRef
16.
B.V. Chakravarthi, S. Nepal, S. Varambally, Genomic and epigenomic alterations in cancer. Am. J. Pathol. 186, 1724–1735 (2016)PubMedCrossRef
17.
R.J. Kurman, I.-M. Shih, The origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. Am. J. Surg. Pathol. 34, 433–443 (2010)PubMedPubMedCentralCrossRef
18.
N.N. Nik, R. Vang, I.M. Shih, R.J. Kurman, Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu. Rev. Pathol. 9, 27–45 (2014)PubMedCrossRef
19.
N. Colombo, M. Peiretti, A. Garbi, S. Carinelli, C. Marini, C. Sessa, Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, 20–26 (2012)
20.
W.D. Foulkes, M. Gore, W.G.M. Cluggage, Rare non-epithelial ovarian neoplasms: pathology, genetics and treatment. Gynecol. Oncol. 142, 190–198 (2016)PubMedCrossRef
21.
M. Köbel, S.E. Kalloger, D.G. Huntsman, J.L. Santos, K.D. Swenerton, J.D. Seidman, C.B. Gilks, Cheryl Brown ovarian cancer outcomes unit of the British Columbia Cancer Agency, Vancouver BC. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int. J. Gynecol. Pathol. 29, 203–211 (2010)PubMedCrossRef
22.
J. Prat, New insights into ovarian cancer pathology. Ann. Oncol. 23 (Suppl 10), 111–117 (2012)
23.
A. Halon, V. Materna, M. Drag-Zalesinska, E. Nowak-Markwitz, T. Gansukh, P. Donizy, M. Spaczynski, M. Zabel, M. Dietel, H. Lage, P. Surowiak, Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol. Oncol. Res. 17, 511–518 (2011)PubMedPubMedCentralCrossRef
24.
R.J. Kurman, I.M. Shih, The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am. J. Pathol. 186, 733–747 (2016)PubMedCrossRef
25.
Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011)CrossRef
26.
A. Bamias, S. Pignata, E. Pujade-Lauraine, Angiogenesis: a promising therapeutic target for ovarian cancer. Crit. Rev. Oncol. Hematol. 84, 314–326 (2012)PubMedCrossRef
27.
N.G. Gavalas, M. Liontos, S.P. Trachana, T. Bagratuni, C. Arapinis, C. Liacos, M.A. Dimopoulos, A. Bamias, Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int. J. Mol. Sci. 14, 15885–15909 (2013)PubMedPubMedCentralCrossRef
28.
J. Farley, W.E. Brady, V. Vathipadiekal, H.A. Lankes, R. Coleman, M.A. Morgan, R. Mannel, S.D. Yamada, D. Mutch, W.H. Rodgers, M. Birrer, D.M. Gershenson, Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 14, 134–140 (2013)PubMedPubMedCentralCrossRef
29.
L.M. Landrum, J. Java, C.A. Mathews, G.S. Lanneau, L.J. Copeland, D.K. Armstrong, J.L. Walker, Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a gynecologic oncology group study. Gynecol. Oncol. 130, 12–18 (2013)PubMedPubMedCentralCrossRef
30.
I. Romero, R.C. Bast Jr., Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 153, 1593–1602 (2012)PubMedPubMedCentralCrossRef
31.
Y. Yang-Hartwich, M.G. Soteras, Z.P. Lin, J. Holmberg, N. Sumi, V. Craveiro, M. Liang, E. Romanoff, J. Bingham, F. Garofalo, A. Alvero, G. Mor, p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene 34, 3605–3616 (2015)PubMedCrossRef
32.
O. Caron, Oncogenetics in the management of ovarian cancer: state-of-the art. Gynecol. Obstet. Fertil. 43, 335–337 (2015)PubMedCrossRef
33.
A.A. Ahmed, D. Etemadmoghadam, J. Temple, A.G. Lynch, M. Riad, R. Sharma, C. Stewart, S. Fereday, C. Caldas, A. Defazio, D. Bowtell, J.D. Brenton, Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Med. Surg. Pathol. 221, 49–56 (2010)
34.
R. Wu, S.J. Baker, T.C. Hu, K.M. Norman, E.R. Fearon, K.R. Cho, Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am. J. Pathol. 182, 1391–1399 (2013)PubMedPubMedCentralCrossRef
35.
J. Prat, Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 460, 237–249 (2012)PubMedCrossRef
36.
R.D.A. Weren, A.R. Mensenkamp, M. Simons, A. Eijkelenboom, A.S. Sie, H. Ouchene, M. van Asseldonk, E.B. Gomez-Garcia, M.J. Blok, J.A. de Hullu, M.R. Nelen, A. Hoischen, J. Bulten, B.B.J. Tops, N. Hoogerbrugge, M.J.L. Ligtenberg, Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas. Hum. Mutat. (2016). doi:10.​1002/​humu.​23137 PubMedPubMedCentral
37.
K.P. Pennington, T. Walsh, M.I. Harrell, M.K. Lee, C.C. Pennil, M.H. Rendi, A. Thornton, B.M. Norquist, S. Casadei, A.S. Nord, K.J. Agnew, C.C. Pritchard, S. Scroggins, R.L. Garcia, M. King, E.M. Swisher, Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764–775 (2014)PubMedCrossRef
38.
J.R. McLaughlin, B. Rosen, J. Moody, T. Pal, I. Fan, P.A. Shaw, H.A. Risch, T.A. Sellers, P. Sun, S.A. Narod, Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J. Natl. Cancer Inst. 105, 141–148 (2013)PubMedPubMedCentralCrossRef
39.
S.B. Kaye, J. Lubinski, U. Matulonis, J.E. Ang, C. Gourley, B.Y. Karlan, A. Amnon, K.M. BellMcGuinn, L.M. Chen, M. Friedlander, T. Safra, I. Vergote, M. Wickens, E.S. Lowe, J. Carmichael, B. Kaufman, I.I. Phase, Open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30, 372–379 (2012)PubMedCrossRef
40.
J.F. Liu, P.A. Konstantinopoulos, U.A. Matulonis, PARP inhibitors in ovarian cancer: current status and future promise. Gynecol. Oncol. 133, 362–369 (2014)PubMedCrossRef
41.
Y. Hirotsu, H. Nakagomi, I. Sakamoto, K. Amemiya, H. Mochizuki, M. Omata, Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol. Genet. Genomic. Med. 3, 121–129 (2015)PubMedCrossRef
42.
C.M. Strom, S. Rivera, C. Elzinga, T. Angeloni, S.H. Rosenthal, D. Goos-Root, M. Siaw, J. Platt, C. Braastadt, L. Cheng, D. Ross, W. Sun, Development and validation of a next-generation sequencing assay for BRCA1 and BRCA2 variants for the clinical laboratory. PLoS One 10, e0136419 (2015)PubMedPubMedCentralCrossRef
43.
J.B. Hiatt, C.C. Pritchard, S.J. Salipante, B.J. O'Roak, J. Shendure, Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res. 23, 843–854 (2013)PubMedPubMedCentralCrossRef
44.
P. Bottoni, R. Scatena, The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv. Exp. Med. Biol. 867, 229–244 (2015)PubMedCrossRef
45.
V.A. Moyer, Screening for ovarian cancer: US preventive services task force reaffirmation recommendation statement. Ann. Intern. Med. 157, 900–904 (2012)PubMedCrossRef
46.
S.S. Buys, E. Partridge, A. Black, C.C. Johnson, L. Lamerato, C. Isaacs, D.J. Reding, R.T. Greenlee, L.A. Yokochi, B. Kessel, E.D. Crawford, T.R. Church, G.L. Andriole, J.L. Weissfeld, M.N. Fouad, D. Chia, B. O'Brien, L.R. Ragard, J.D. Clapp, J.M. Rathmell, T.L. Riley, P. Hartge, P.F. Pinsky, C.S. Zhu, G. Izmirlian, B.S. Kramer, A.B. Miller, J.L. Xu, P.C. Prorok, J.K. Gohagan, C.D. Berg, PLCO Project Team, Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305, 2295–2303 (2011)PubMedCrossRef
47.
I.J. Jacobs, U. Menon, A. Ryan, A. Gentry-Maharaj, M. Burnell, J.K. Kalsi, N.N. Amso, S. Apostolidou, E. Benjamin, D. Cruickshank, D.N. Crump, S.K. Davies, A. Dawnay, S. Dobbs, G. Fletcher, J. Ford, K. Godfrey, R. Gunu, M. Habib, R. Hallett, J. Herod, H. Jenkins, C. Karpinskyj, S. Leeson, S.J. Lewis, W.R. Liston, A. Lopes, T. Mould, J. Murdoch, D. Oram, D.J. Rabideau, K. Reynolds, I. Scott, M.W. Seif, A. Sharma, N. Singh, J. Taylor, F. Warburton, M. Widschwendter, K. Williamson, R. Woolas, L. Fallowfield, A.J. McGuire, S. Campbell, M. Parmar, S.J. Skates, Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet 387, 945–956 (2016)PubMedPubMedCentralCrossRef
48.
49.
R.G. Moore, M.C. Miller, P. Disilvestro, L.M. Landrum, W. Gajewski, J.J. Ball, S.J. Skates, Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet. Gynecol. 118, 280 (2011)PubMedPubMedCentralCrossRef
50.
T. Van Gorp, I. Cadron, E. Despierre, A. Daemen, K. Leunen, F. Amant, D. Timmerman, B. De Moor, I. Vergote, HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Brit. J. Cancer 104, 863–870 (2011)PubMedPubMedCentralCrossRef
51.
Y. Xu, R. Zhong, J. He, R. Ding, H. Lin, Y. Deng, L. Zhou, X. Li, J. Jiang, Y. Bao, X. Luo, C. Duan, Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: results from 1021 cases in South China. Clin. Biochem. 49, 32–40 (2016)PubMedCrossRef
52.
M.R. Andersen, B.A. Goff, K.A. Lowe, N. Scholler, L. Bergan, C.W. Drescher, P. Paley, N. Urban, Use of a symptom index, CA125, and HE4 to predict ovarian cancer. J. Gynecol. Oncol. 116, 378–383 (2010)CrossRef
53.
T. Edgell, G. Martin-Roussety, G. Barker, D.J. Autelitano, D. Allen, P. Grant, G.E. Rice, Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J. Cancer Res. Clin. Oncol. 136, 1079–1088 (2010)PubMedPubMedCentralCrossRef
54.
Z. Yurkovetsky, S. Skates, A. Lomakin, B. Nolen, T. Pulsipher, F. Modugno, J. Marks, A. Godwin, E. Gorelik, I. Jacobs, U. Menon, K. Lu, D. Badgwell, R.C. Bast Jr., A.E. Lokshin, Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 28, 2159–2166 (2010)PubMedPubMedCentralCrossRef
55.
E. Kipps, D.S. Tan, S.B. Kaye, Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat. Rev. Cancer 13, 273–282 (2013)PubMedPubMedCentralCrossRef
56.
K.L. Terry, H. Schock, R.T. Fortner, A. Hüsing, R.N. Fichorova, H.S. Yamamoto, A.F. Vitonis, T. Johnson, K. Overvad, A. Tjønneland, M.C. Boutron-Ruault, S. Mesrine, G. Severi, L. Dossus, S. Rinaldi, H. Boeing, V. Benetou, P. Lagiou, A. Trichopoulou, V. Krogh, E. Kuhn, S. Panico, H.B. Bueno-de-Mesquita, N.C. Onland-Moret, P.H. Peeters, I.T. Gram, E. Weiderpass, E.J. Duell, M.J. Sanchez, E. Ardanaz, N. Etxezarreta, C. Navarro, A. Idahl, E. Lundin, K. Jirström, J. Manjer, N.J. Wareham, K.T. Khaw, K. Smith Byrne, R.C. Travis, M.J. Gunter, M.A. Merritt, E. Riboli, D. Cramer, R. Kaaks, A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort. Clin. Cancer Res. 22, 1078–10432 (2016)CrossRef
57.
P. Vinken, S. Starckx, E. Barale-Thomas, A. Looszova, M. Sonee, N. Goeminne, L. Versmissen, K. Buyens, A. Lampo, Tissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats. Toxicol. Pathol. 40, 1049–1062 (2012)PubMedCrossRef
58.
Z. Zhang, D.W. Chan, The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidem. Biomar. 19, 2995–2999 (2010)CrossRef
59.
R.W. Miller, A. Smith, C.P. DeSimone, L. Seamon, S. Goodrich, I. Podzielinski, L. Sokoll, J.R. van Nagell Jr., Z. Zhang, F.R. Ueland, Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet. Gynecol. 117, 1298–1306 (2011)CrossRef
60.
B.H. Shadfan, A.R. Simmons, G.W. Simmons, A. Ho, J. Wong, K.H. Lu, R.C. Bast, J.T. McDevitt, A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prev. Res. 8, 37–48 (2015)CrossRef
61.
Y.W. Kim, S.M. Bae, H. Lim, Y.J. Kim, W.S. Ahn, Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS One 7, e44960 (2012)PubMedPubMedCentralCrossRef
62.
S. Kato, L. Abarzua-Catalan, C. Trigo, A. Delpiano, C. Sanhueza, K. García, C. Ibañez, K. Hormazábal, D. Diaz, J. Brañes, E. Castellón, E. Bravo, G. Owen, M. Cuello, Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women. Oncotarget 6, 21100–21119 (2015)PubMedPubMedCentralCrossRef
63.
N.M.A. White, T.F. Chow, S. Mejia-Guerrero, M. Diamandis, Y. Rofael, H. Faragalla, G.M. Yousef, Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Brit. J. Cancer 102, 1244–1253 (2010)PubMedPubMedCentralCrossRef
64.
M.A.H. El Sherbini, M.M. Sallam, E.A.K. Shaban, A.H. El-Shalakany, Diagnostic value of serum kallikrein-related peptidases 6 and 10 versus CA125 in ovarian cancer. Int. J. Gynecol. Cancer 21, 625–632 (2011)PubMedCrossRef
65.
S.C.L. Koh, C.Y. Huak, D. Lutan, J. Marpuang, S. Ketut, N.G. Budiana, N.K.H. Hoan, Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer. J. Gynecol. Oncol. 23, 175–181 (2012)PubMedPubMedCentralCrossRef
66.
M.K. Siu, H.Y. Chan, D.S. Kong, E.S. Wong, O.G. Wong, H.Y. Ngan, K.F. Tam, H. Zhang, Z. Li, Q.K. Chan, S.W. Tsao, p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc. Natl. Acad. Sci. U. S. A. 107, 18622–18627 (2010)PubMedPubMedCentralCrossRef
67.
X. Xia, Q. Ma, X. Li, T. Ji, P. Chen, H. Xu, S. Liao, Z. Han, R. Liu, T. Zhu, S. Wang, G. Xu, L. Meng, J. Zhou, D. Ma, Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer 11, 399 (2011)PubMedPubMedCentralCrossRef
68.
K. Wurz, R.L. Garcia, B.A. Goff, P.S. Mitchell, J.H. Lee, M. Tewari, E.M. Swisher, MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosom. Cancer 49, 577–584 (2010)PubMedPubMedCentral
69.
L. Szabova, C. Yin, S. Bupp, T.M. Guerin, J.J. Schlomer, D.B. Householder, M.L. Baran, M. Yi, Y. Song, W. Sun, J.E. McDunn, Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res. 72, 4141–4153 (2012)PubMedPubMedCentralCrossRef
70.
K. Avraam, K. Pavlakis, C. Papadimitriou, T. Vrekoussis, T. Panoskaltsis, I. Messini, E. Patsouris, The prognostic and predictive value of ERCC-1, p53, bcl-2 and bax in epithelial ovarian cancer. Eur. J. Gynaecol. Oncol. 32, 516–520 (2010)
71.
F. Kong, C. Sun, Z. Wang, L. Han, D. Weng, Y. Lu, G. Chen, miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J. Huazhong Univ. Sci. Technolog. Med. Sci. 31, 543–549 (2011)PubMedCrossRef
72.
S. Lawicki, G.E. Będkowska, E. Gacuta-Szumarska, M. Szmitkowski, The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J. Ovarian Res. 6, 1 (2013)CrossRef
73.
M.R. Russell, M.J. Walker, A.J. Williamson, A. Gentry-Maharaj, A. Ryan, J. Kalsi, S. Skates, A. D'Amato, C. Dive, M. Pernemalm, P.C. Humphryes, Protein Z: a putative novel biomarker for early detection of ovarian cancer. Int. J. Cancer 138, 2984–2992 (2016)PubMedPubMedCentralCrossRef
74.
K.M. Nieman, H.A. Kenny, C.V. Penicka, A. Ladanyi, R. Buell-Gutbrod, M.R. Zillhardt, I.L. Romero, M.S. Carey, G.B. Mills, G.S. Hotamisligil, S.D. Yamada, Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498–1503 (2011)PubMedPubMedCentralCrossRef
75.
M. Zou, X. Zhang, C. Xu, IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells. Cell. Oncol. 39, 47–57 (2016)CrossRef
76.
S.J. Bensinger, H.R. Christofk, New aspects of the Warburg effect in cancer cell biology, Semin. Cell. Dev. Biol. 23, 352–361 (2012)CrossRef
77.
78.
A.J. Levine, A.M. Puzio-Kuter, The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340–1344 (2010)PubMedCrossRef
79.
M.G. Vander Heiden, J.W. Locasale, K.D. Swanson, H. Sharfi, G.J. Heffron, D. Amador-Noguez, H.R. Christofk, G. Wagner, J.D. Rabinowitz, J.M. Asara, L.C. Cantley, Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492–1499 (2010)PubMedCrossRef
80.
M.Y. Fong, J. McDunn, S.S. Kakar, Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 6, e19963 (2011)PubMedPubMedCentralCrossRef
81.
A. Beach, H.G. Zhang, M.Z. Ratajczak, S.S. Kakar, Exosomes: an overview of biogenesis, composition and role in ovarian cancer. J. Ovarian Res. 7, 14 (2014)PubMedPubMedCentralCrossRef
82.
A. Caivano, F. La Rocca, V. Simeon, M. Girasole, S. Dinarelli, I. Laurenzana, A. De Stradis, L. De Luca, S. Trino, A. Traficante, G. D’Arena, G. Mansueto, O. Villani, G. Pietrantuono, L. Laurenti, L. Del Vecchio, P. Musto, MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. Cell. Oncol. (2016) doi:10.​1007/​s13402-016-0300-x
83.
L. Balaj, R. Lessard, L. Dai, Y.J. Cho, S.L. Pomeroy, X.O. Breakefield, J. Skog, Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011)PubMedPubMedCentralCrossRef
84.
A. Waldenstrom, N. Genneback, U. Hellman, G. Ronquist, Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells. PLoS One 7, e34653 (2012)PubMedPubMedCentralCrossRef
85.
C.A. Maguire, L. Balaj, S. Sivaraman, M.H. Crommentuijn, M. Ericsson, L. Mincheva-Nilsson, V. Baranov, D. Gianni, B.A. Tannous, M. Sena-Esteves, X.O. Breakefield, Microvesicle-associated AAV vector as a novel gene delivery system. Mol. Ther. 20, 960–971 (2012)PubMedPubMedCentralCrossRef
86.
87.
K.D.P. Dorayappan, J.J. Wallbillich, D.E. Cohn, K. Selvendiran, The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol. Oncol. 142, 199–205 (2016)PubMedCrossRef
88.
A. Bobrie, M. Colombo, G. Raposo, C. Thery, Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 12, 1659–1668 (2011)PubMedCrossRef
89.
I. Nazarenko, S. Rana, A. Baumann, J. McAlear, A. Hellwig, M. Trendelenburg, G. Lochnit, K.T. Preissner, M. Zöller, Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 70, 1668–1678 (2010)PubMedCrossRef
90.
R. Cappellesso, A. Tinazzi, T. Giurici, F. Simonato, V. Guzzardo, L. Ventura, M. Crescenzi, S. Chiarelli, A. Fassina, Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol. 122, 685–693 (2014)PubMedCrossRef
91.
O. Vaksman, C. Tropé, B. Davidson, R. Reich, Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 35, 2113–2120 (2014)PubMedCrossRef
92.
A. Liga, A.D.B. Vliegenthart, W. Oosthuyzen, J.W. Dear, M. Kersaudy-Kerhoas, Exosome isolation: a microfluidic road-map. Lab Chip 15, 2388–2394 (2015)PubMedCrossRef
93.
D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011)PubMedCrossRef
94.
R. Paduch, The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell. Oncol. 39, 397–410 (2016)
95.
L.H.A. Broersen, G.W. van Pelt, R.A.E.M. Tollenaar, W.E. Mesker, Clinical application of circulating tumor cells in breast cancer. Cell. Oncol. 37, 9–15 (2014)CrossRef
96.
C. Van Berckelaer, A.J. Brouwers, D.J.E. Peeters, W. Tjalma, X.B. Trinh, P.A. van Dam, Current and future role of circulating tumor cells in patients with epithelial ovarian cancer. Eur. J. Surg. Oncol. (2016). doi:10.​1016/​j.​ejso.​2016.​05.​010 PubMed
97.
C. Van Berckelaer, A.J. Brouwers, D.J. Peeters, W. Tjalma, X.B. Trinh, P.A. van Dam, Current and future role of circulating tumor cells in patients with epithelial ovarian cancer. Eur. J. Surg. Oncol. (2016). doi:10.​1016/​j.​ejso.​2016.​05.​010 PubMed
98.
E. Obermayr, D.C. Castillo-Tong, D. Pils, P. Speiser, I. Braicu, T. Van Gorp, S. Mahner, J. Sehouli, I. Vergote, R. Zeillinger, Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance—a study of the OVCAD consortium. Gynecol. Oncol. 128, 15–21 (2013)PubMedCrossRef
99.
E. Obermayr, F. Sanchez-Cabo, M.K.M. Tea, C.F. Singer, M. Krainer, M.B. Fischer, J. Sehouli, A. Reinthaller, R. Horvat, G. Heinze, D. Tong, Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer 10, 666 (2010)PubMedPubMedCentralCrossRef
100.
K. Kolostova, M. Pinkas, A. Jakabova, E. Pospisilova, P. Svobodova, J. Spicka, M. Cegan, R. Matkowski, V. Bobek, Molecular characterization of circulating tumor cells in ovarian cancer. Am. J. Cancer Res. 6, 973–980 (2016)PubMedPubMedCentral
101.
K. Kolostova, R. Matkowski, M. Jędryka, K. Soter, M. Cegan, M. Pinkas, A. Jakabova, J. Pavlasek, J. Spicka, V. Bobek, The added value of circulating tumor cells examination in ovarian cancer staging. Am. J. Cancer Res. 5, 3363–3375 (2015)PubMedPubMedCentral
102.
R.R. Langley, I.J. Fidler, The seed and soil hypothesis revisited—the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 128, 2527–2535 (2011)PubMedPubMedCentralCrossRef
103.
E. Kolwijck, J. Kos, N. Obermajer, P.N. Span, C.M. Thomas, L.F. Massuger, F.C. Sweep, The balance between extracellular cathepsins and cystatin C is of importance for ovarian cancer. Eur. J. Clin. Investig. 40, 591–599 (2010)CrossRef
104.
105.
S.M. Khan, H.M. Funk, S. Thiolloy, T.L. Lotan, J. Hickson, G.S. Prins, C.W. Rinker-Schaeffer, In vitro metastatic colonization of human ovarian cancer cells to the omentum. Clin. Exp. Metastasis 27, 185–196 (2010)PubMedCrossRef
106.
M. Galea, G. Gauci, J. Calleja-Agius, P. Schembri-Wismayer, Peritoneal biomarkers in the early detection of ovarian cancer. Minerva. Ginecol. (2016, in press)
107.
R. Drake, A.W. Vogl, A.W.M. Mitchel, Gray's anatomy for students (Churchill Livingstone/Elsevier, Philadelphia, 2010)
108.
U. Kucukgoz Gulec, S. Paydas, A.B. Guzel, S. Buyukkurt, G. Seydaoglu, M.A. Vardar, Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia. Med. Oncol. 29, 2937–2943 (2012)PubMedCrossRef
109.
V.M. Peterson, C.M. Castro, J. Chung, N.C. Miller, A.V. Ullal, M.D. Castano, R.T. Penson, H. Lee, M.J. Birrer, R. Weissleder, Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proc. Natl. Acad. Sci. U. S. A. 110, E4978–E4986 (2013)PubMedPubMedCentralCrossRef
110.
L.M. Amon, W. Law, M.P. Fitzgibbon, J.A. Gross, K. O'Briant, A. Peterson, C. Drescher, D.B. Martin, M. McIntosh, Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. PLoS One 5, e11137 (2010)PubMedPubMedCentralCrossRef
111.
M.A. Dawson, T. Kouzarides, Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27 (2012)PubMedCrossRef
112.
H. Easwaran, H.C. Tsai, S.B. Baylin, Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell 54, 716–727 (2014)PubMedPubMedCentralCrossRef
113.
A. Ferraro, Altered primary chromatin structures and their implications in cancer development. Cell. Oncol. 39, 195–210 (2016)CrossRef
114.
115.
116.
117.
J. Tost, I.G. Gut, in Molecular Diagnostics (Third Edition), ed. by George P. Patrinos, Philip B. Danielson and Wilhelm J. Ansorge (Elsevier/Academic Press, Amsterdam, 2017), pp.103–139. doi:10.​1016/​B978-0-12-802971-8.​00007-9
118.
T.E. Liggett, A. Melnikov, Q. Yi, C. Replogle, W. Hu, J. Rotmensch, A. Kamat, A.K. Sood, V. Levenson, Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol. Oncol. 120, 113–120 (2011)PubMedCrossRef
119.
C. Marsit, B. Christensen, Epigenetic Alterations in Oncogenesis, ed. by Adam R. Karpf (Springer, Berlin Heidelberg New York) (2013), pp. 233–252
120.
L.M.S. Seeber, P.J. Van Diest. Epigenetics in Cancer Epigenetics: Methods and Protocols, ed. by G. D. Ramona and V. Mukesh (Springer, Berlin Heidelberg New York, 2012), pp 253–269.
121.
J.A.T. Pepin, H. Cardenas, C. Moore, S. Condello, J. Guanglong, L. Yunlong, D. Matei, Epigenetic vulnerabilities in ovarian cancer. Cancer Res. 76, 4486–4486 (2016)CrossRef
122.
M. Longacre, N.A. Snyder, G. Housman, M. Leary, K. Lapinska, S. Heerboth, A. Willbanks, S. Sarkar, A comparative analysis of genetic and epigenetic events of breast and ovarian cancer related to tumorigenesis. Int. J. Mol. Sci. 17, 759 (2016)PubMedCentralCrossRef
123.
H. Mirzaei, F. Yazdi, R. Salehi, H.R. Mirzaei, SiRNA and epigenetic aberrations in ovarian cancer. J. Cancer Res. Ther. 12, 498–508 (2016)PubMedCrossRef
124.
M. Kaur, A. Singh, K. Singh, S. Gupta, M. Sachan, Development of a multiplex MethyLight assay for the detection of DAPK1 and SOX1 methylation in epithelial ovarian cancer in a north Indian population. Genes Genet. Syst. (2016). doi:10.​1266/​ggs.​15-00051 PubMed
125.
Y.P. Liao, L.Y. Chen, R.L. Huang, P.H. Su, M.W. Chan, C.C. Chang, M.H. Yu, P.H. Wang, M.S. Yen, K.P. Nephew, H.C. Lai, Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients. Hum. Mol. Genet. 23, 1894–1906 (2014)PubMedCrossRef
126.
X. Lin, X. Shang, G. Manorek, S. Howell, Control of integrin expression and signaling by claudin-3 and claudin-4 in ovarian cancer. Cancer Res. 73, 211–211 (2013)CrossRef
127.
Y.F. Huang, W.F. Cheng, Y.P. Wu, Y.M. Cheng, K.F. Hsu, C.Y. Chou, Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr. Relat. Cancer 21, 217–229 (2014)PubMedCrossRef
128.
D.J. Marsh, J.S. Shah, A.J. Cole, Histones and their modifications in ovarian cancer–drivers of disease and therapeutic targets. Front Oncol. 4, 144 (2014)PubMedPubMedCentralCrossRef
129.
K.R. Davis, K.J. Flower, J.V. Borley, C.S.M. Wilhelm-Benartzi, Cell-free circulating tumor DNA methylation in high-grade serous ovarian cancer. Cancer Res. 76, 3154–3154 (2016)CrossRef
130.
S.N. Akers, K. Moysich, W. Zhang, G. Collamat Lai, A. Miller, S. Lele, K. Odunsi, A.R. Karpf, LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. Gynecol. Oncol. 132, 462–467 (2014)PubMedCrossRef
131.
A. DiazLuis, A. Bardelli, Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579–586 (2014)CrossRef
132.
H. Holger, M. Esteller, DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 13, 679–692 (2012)CrossRef
133.
C. Montavon, B.S. Gloss, K. Warton, C.A. Barton, A.L. Statham, J.P. Scurry, B. Tabor, T.V. Nguyen, W. Qu, G. Samimi, N.F. Hacker, Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol. Oncol. 124, 582–588 (2012)PubMedCrossRef
134.
F. Yin, X. Liu, D. Li, Q. Wang, W. Zhang, L. Li, Tumor suppressor genes associated with drug resistance in ovarian cancer (review). Oncol. Rep. 30, 3–10 (2013)PubMed
135.
B. Zhang, F.F. Cai, X.Y. Zhong, An overview of biomarkers for the ovarian cancer diagnosis. Eur. J. Obstet. Gynecol. 158, 119–123 (2011)
136.
B.L. Valle, E. Kuhn, D. Sidransky, R. Guerrero-Preston, DNA promoter hypermethylation of genes as potential diagnostic and prognostic biomarkers for ovarian cancer. Cancer Res. 75, 2960–2960 (2015)CrossRef
137.
A. Dobrovic, T. Mikeska, K. Alsop, I. Candiloro, J. George, G. Mitchell, D. Bowtell, Constitutional BRCA1 methylation is a major predisposition factor for high-grade serous ovarian cancer. Cancer Res. 74, 290–290 (2014)CrossRef
138.
O.A. Al-Shabanah, M.M. Hafez, Z.K. Hassan, M.M. Sayed-Ahmed, W.N. Abozeed, A. Alsheikh, S.S. Al-Rejaie, Methylation of SFRPs and APC genes in ovarian cancer infected with high risk human papillomavirus. Asian Pac. J. Cancer Prev. 15, 2719–2725 (2013)CrossRef
139.
R. Bhagat, S. Chadaga, C.S. Premalata, G. Ramesh, C. Ramesh, V.R. Pallavi, L. Krishnamoorthy, Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development. Cell. Oncol. 35, 473–479 (2012)CrossRef
140.
V. Taucher, H. Mangge, J. Haybaeck, Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application. Cell. Oncol. 39, 295–318 (2016)CrossRef
141.
M. Vitiello, A. Tuccoli, L. Poliseno, Long non-coding RNAs in cancer: implications for personalized therapy. Cell. Oncol. 38, 17–28 (2015)CrossRef
142.
143.
M. Acunzo, G. Romano, D. Wernicke, C.M. Croce, MicroRNA and cancer–a brief overview. Adv. Biol. Regul. 57, 1–9 (2015)PubMedCrossRef
144.
L. Ayaz, F. Cayan, Ş. Balci, A. Görür, S. Akbayir, H. YıldırımYaroğlu, N. DoğruerUnal, L. Tamer, Circulating microRNA expression profiles in ovarian cancer. J. Obstet. Gynaecol. 4, 620–624 (2014)CrossRef
145.
S. Zhang, Z. Lu, A.K. Unruh, C. Ivan, K.A. Baggerly, G.A. Calin, Z. Li, R.C. Bast Jr., X.F. Le, Clinically relevant microRNAs in ovarian cancer. Mol. Cancer Res. 13, 393–401 (2015)PubMedCrossRef
146.
M. Bagnoli, L. De Cecco, A. Granata, R. Nicoletti, E. Marchesi, P. Alberti, B. Valeri, M. Libra, M. Barbareschi, F. Raspagliesi, D. Mezzanzanica, S. Canevari, Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2, 1265–1278 (2011)PubMedPubMedCentralCrossRef
147.
S.F. Hausler, A. Keller, P.A. Chandran, K. Ziegler, K. Zipp, S. Heuer, M. Krockenberger, J.B. Engel, A. Hönig, M. Scheffler, J. Dietl, J. Wischhusen, Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br. J. Cancer 103, 693–700 (2010)PubMedPubMedCentralCrossRef
148.
Y.W. Chung, H.S. Bae, J.Y. Song, J.K. Lee, N.W. Lee, T. Kim, K.W. Lee, Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients. Int. J. Gynecol. Cancer 23, 673–679 (2013)PubMedCrossRef
149.
H. Zheng, L. Zhang, Y. Zhao, D. Yang, F. Song, Y. Wen, Q. Hao, Z. Hu, W. Zhang, K. Chen, Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One 8, e77853 (2013)PubMedPubMedCentralCrossRef
150.
I. Shapira, M. Oswald, J. Lovecchio, H. Khalili, A. Menzin, J. Whyte, L. Dos Santos, S. Liang, T. Bhuiya, M. Keogh, C. Mason, Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br. J. Cancer 110, 976–983 (2014)PubMedCrossRef
151.
C.W. Kan, V.M. Howell, M.A. Hahn, D.J. Marsh, Genomic alterations as mediators of miRNA dysregulation in ovarian cancer. Genes Chromosom. Cancer 54, 1–19 (2015)PubMedCrossRef
152.
R. Langhe, L. Norris, F.A. Saadeh, G. Blackshields, R. Varley, A. Harrison, N. Gleeson, C. Spillane, C. Martin, D.M. O'Donnell, T. D'Arcy, J. O'Leary, S. O'Toole, A novel serum microRNA panel to discriminate benign from malignant ovarian disease. Cancer Lett. 356, 628–636 (2015)PubMedCrossRef
153.
S. Leskelä, L.J. Leandro-García, M. Mendiola, J. Barriuso, L. Inglada-Pérez, I. Muñoz, B. Martínez-Delgado, A. Redondo, J. de Santiago, M. Robledo, D. Hardisson, The miR-200 family controls β-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr. Relat. Cancer 18, 85–95 (2011)PubMedCrossRef
154.
S. Marchini, D. Cavalieri, R. Fruscio, E. Calura, D. Garavaglia, I.F. Nerini, C. Mangioni, G. Cattoretti, L. Clivio, L. Beltrame, D. Katsaros, Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol. 12, 273–285 (2011)PubMedCrossRef
155.
K. Nakamura, K. Sawada, A. Yoshimura, Y. Kinose, E. Nakatsuka, T. Kimura, Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol. Cancer 15, 48 (2016)PubMedPubMedCentralCrossRef
156.
J. Zhou, G. Gong, H. Tan, F. Dai, X. Zhu, Y. Chen, J. Wang, Y. Liu, P. Chen, X. Wu, J. Wen, Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. Oncol. Rep. 33, 2915–2923 (2015)PubMed
157.
Y. Chen, L. Zhang, Q. Hao, Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation. Cancer Cell Int. 13, 86 (2013)PubMedPubMedCentralCrossRef
Metadaten
Titel
Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer
verfasst von
Khalid El Bairi
Abdul Hafeez Kandhro
Adel Gouri
Wafaa Mahfoud
Noureddine Louanjli
Brahim Saadani
Said Afqir
Mariam Amrani
Publikationsdatum
15.12.2016
Verlag
Springer Netherlands
Erschienen in
Cellular Oncology / Ausgabe 2/2017
Print ISSN: 2211-3428
Elektronische ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-016-0309-1

Weitere Artikel der Ausgabe 2/2017

Cellular Oncology 2/2017 Zur Ausgabe

Original Paper

CDKN2A-p53 mediated antitumor effect of Lupeol in head and neck cancer

Original Paper

microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression

Original Paper

HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation

Original Paper

Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells

Original Paper

Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis

Original Paper

microRNA-145 modulates epithelial-mesenchymal transition and suppresses proliferation, migration and invasion by targeting SIP1 in human cervical cancer cells

Neu im Fachgebiet Pathologie

Open Access 15.04.2024 | Biomarker | Schwerpunkt: Next Generation Pathology

Molekularpathologische Untersuchungen im Wandel der Zeit

11.04.2024 | Pathologie | Schwerpunkt: Next Generation Pathology

Vergleichende Pathologie in der onkologischen Forschung

Open Access 08.04.2024 | GIST | CME

Gastrointestinale Stromatumoren
Wo stehen wir?

03.04.2024 | Zielgerichtete Therapie | Schwerpunkt: Next Generation Pathology

Personalisierte Medizin in der Onkologie